TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17580251

Group type: EXPERIMENTAL
Intervention: Molecular tools for diagnosis and treatment of aortic disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers for monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular mechanisms investigation
Number of subjects: 0
Study: 15231009

Group type: EXPERIMENTAL
Intervention: 10 kcal/kgLBM/day energy availability treatment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All restricted energy availability treatments (10, 20, or 30 kcal/kgLBM/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Energy availability treatments (20 and 30 kcal/kgLBM/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Energy availability treatments
Number of subjects: 29
Study: 12235954

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual chamber ICDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biventricular ICDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICDs
Number of subjects: 0
Study: 10806744

Group type: EXPERIMENTAL
Intervention: 25 micrograms misoprostol
Number of subjects: 48

Group type: COMPARATOR
Intervention: 50 micrograms misoprostol
Number of subjects: 48
Study: 7744561

Group type: EXPERIMENTAL
Intervention: 1 microT (10 mG) electromagnetic fields applied over the right temporal lobe
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 microT (10 mG) electromagnetic fields applied over the left temporal lobe
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 microT (10 mG) electromagnetic fields applied over both temporal lobes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham-conditions
Number of subjects: 40
Study: 2688995

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (200 IU daily) with daily calcium supplement of 500 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (calcium) group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (age-matched healthy women without calcium supplementation)
Number of subjects: 37
Study: 4574042

Group type: EXPERIMENTAL
Intervention: Prophylactic C.N.S. treatment (craniospinal irradiation plus intrathecal methotrexate)
Number of subjects: 177

Group type: COMPARATOR
Intervention: No prophylactic C.N.S. treatment
Number of subjects: 177
Study: 31958985

Group type: EXPERIMENTAL
Intervention: Pre-training inter-rater reliability
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pre-training intra-rater reliability
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Post-training inter-rater reliability
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Post-training intra-rater reliability
Number of subjects: 125
Study: 30292415

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2 mA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1 mA
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study: 27014012

Group type: EXPERIMENTAL
Intervention: tDCS + AE
Number of subjects: 45
Study: 24844332

Group type: EXPERIMENTAL
Intervention: Interleukin-10 (100 ng/100 µL)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interleukin-10 (5 ng/100 µL)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interleukin-10 (25 ng/100 µL)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interleukin-10 (250 ng/100 µL)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 23971019

Group type: EXPERIMENTAL
Intervention: Integrated care approach (IC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care approach (UC)
Number of subjects: 50
Study: 20681811

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HAP) in dry sol gel form
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HAP) in liquid precipitate form
Number of subjects: 45

Group type: COMPARATOR
Intervention: Distilled water (positive control)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 45
Study: 19107263

Group type: EXPERIMENTAL
Intervention: Electronic probing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Manual probing by postgraduate students
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Manual probing by associate professors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Manual probing by undergraduate students
Number of subjects: 30
Study: 16884982

Group type: EXPERIMENTAL
Intervention: Sufentanil-based anesthetic technique
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ketamine and midazolam-based anesthetic technique
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adjuvant use of isoflurane
Number of subjects: 42
Study: 14635083

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.75 mg
Number of subjects: 569

Group type: COMPARATOR
Intervention: Dolasetron 100 mg
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 569
Study: 10939699

Group type: EXPERIMENTAL
Intervention: Dopexamine (2 microg x kg(‐1) x min(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 40
Study: 9316825

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg/70 kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Morphine 10 mg/70 kg
Number of subjects: 16
Study: 8399631

Group type: EXPERIMENTAL
Intervention: Lovastatin (20-40 mg)
Number of subjects: 10
Study: 3528611

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (mean dose 7.8 +/- 1.2 mg/kg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 24

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 24
Study: 2498073

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31301105

Group type: EXPERIMENTAL
Intervention: 4-mm HIGH treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: 4-mm LOW treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: 6-mm HIGH treatment
Number of subjects: 27
Study: 31375879

Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg daily with bevacizumab 15 mg/kg every 21 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bevacizumab 15 mg/kg every 21 days
Number of subjects: 12
Study: 28466533

Group type: EXPERIMENTAL
Intervention: Acute sugar intake from sugar-sweetened beverages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-ingestion of caffeine with sugar
Number of subjects: 0
Study: 27137713

Group type: EXPERIMENTAL
Intervention: Epelsiban (10 to 200 mg single-dose; 10 to 150 mg repeat-dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Epelsiban
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GSK2395448 (metabolite of epelsiban)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Epelsiban and GSK2395448
Number of subjects: 48
Study: 22559997

Group type: EXPERIMENTAL
Intervention: Triple test with two antibiotics and one NSAID or two NSAIDs and one antibiotic performed on the same day (n=22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group with drugs taken on three separate days (n=20)
Number of subjects: 42
Study: 21654249

Group type: EXPERIMENTAL
Intervention: Electrolyzed strongly acidic aqueous solution
Number of subjects: 363

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 363
Study: 19386683

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg daily for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acquisition of a new PPM during follow-up
Number of subjects: 40
Study: 16317024

Group type: EXPERIMENTAL
Intervention: Cerebellar damage
Number of subjects: 15
Study: 12220769

Group type: EXPERIMENTAL
Intervention: Flaxseed (40 g/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hormone replacement therapy (0.625 mg conjugated equine estrogens alone or combined with 100 mg micronized progesterone)
Number of subjects: 25
Study: 10629707

Group type: EXPERIMENTAL
Intervention: Radiation therapy of the breast alone or zones of regional metastasizing (57 patients) with or without adjuvant chemotherapy or hormone therapy (tamoxifen)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (patients with tumor size not exceeding 1 cm)
Number of subjects: 254
Study: 8552892

Group type: EXPERIMENTAL
Intervention: Drug therapy for polymyositis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delta-method approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different transforms for setting confidence limits
Number of subjects: 0
Study: 1674014

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily for 4 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7028258

Group type: EXPERIMENTAL
Intervention: CYT plus bleomycin plus cisplatin (SQ)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: ADR plus 5‐FU plus cisplatin (AD and LC)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Mitomycin (SQ)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Responders to any regimen
Number of subjects: 415

Group type: COMPARATOR
Intervention: CYT plus CCNU (SQ, AD, and LC)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Methotrexate plus doxorubicin plus CYT plus CCNU (MAC) (SQ and AD)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Mitolactol plus ADR (AD and LC)
Number of subjects: 415
Study: 31211782

Group type: EXPERIMENTAL
Intervention: Maternal 25(OH)D
Number of subjects: 5223

Group type: EXPERIMENTAL
Intervention: Maternal calcium
Number of subjects: 5223

Group type: EXPERIMENTAL
Intervention: Calcium (RCTs)
Number of subjects: 5223

Group type: EXPERIMENTAL
Intervention: 25(OH)D (RCTs)
Number of subjects: 5223
Study: 28841903

Group type: EXPERIMENTAL
Intervention: Needle fasciotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited fasciectomy
Number of subjects: 0
Study: 25162948

Group type: EXPERIMENTAL
Intervention: Gauze suction (GSUC)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 104
Study: 23953384

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (three cycles of 5 min ischaemia and 5 min reperfusion in the left upper arm after induction of anaesthesia)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control (no ischaemic preconditioning)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 329
Study: 20581697

Group type: EXPERIMENTAL
Intervention: Sling exercise training (SET) group (n = 14)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CON, n = 10)
Number of subjects: 24
Study: 18437013

Group type: EXPERIMENTAL
Intervention: Thoracoscopic procedure and pleurodesis with dextrose solution (group B)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Thoracoscopic procedure and pleurodesis with talc-dextrose mixed solution (group C)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Thoracoscopic procedure only (group A)
Number of subjects: 141
Study: 16482238

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy (esomeprazole 20 mg, clarithromycin 500 mg, amoxycillin 1 g for 7 days)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 10-day triple therapy (esomeprazole 20 mg, clarithromycin 500 mg, amoxycillin 1 g for 10 days)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen (esomeprazole 20 mg + amoxycillin 1 g for 5 days, followed by esomeprazole 20 mg, clarithromycin 500 mg, tinidazole 500 mg for 5 days)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Comparison of 10-day sequential regimen vs 7-day triple therapy
Number of subjects: 213

Group type: COMPARATOR
Intervention: Comparison of 10-day sequential regimen vs 10-day triple therapy
Number of subjects: 213

Group type: COMPARATOR
Intervention: Comparison of 7-day triple therapy vs 10-day triple therapy
Number of subjects: 213
Study: 12941449

Group type: EXPERIMENTAL
Intervention: Eyes Open in the Dark (EOd)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Eyes Closed (EC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Eyes Open in Daylight (EO)
Number of subjects: 20
Study: 10804906

Group type: EXPERIMENTAL
Intervention: Selective serotonin re-uptake inhibitors (SSRIs)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Untreated PTSD patients
Number of subjects: 9
Study: 8628043

Group type: EXPERIMENTAL
Intervention: Single-item linear analogue self-assessment scale for mood
Number of subjects: 2129

Group type: EXPERIMENTAL
Intervention: 28-item adjective checklist for emotional well-being
Number of subjects: 2129
Study: 1634662

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (continued smoking)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Cigarette smoking cessation (quitters)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (continued smoking) in bypass surgery patients
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Cigarette smoking cessation (quitters) in bypass surgery patients
Number of subjects: 780
Study: 6823861

Group type: EXPERIMENTAL
Intervention: Labetalol (intravenous administration)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Labetalol (prolonged oral therapy)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 7
Study: 30817919

Group type: EXPERIMENTAL
Intervention: Haloperidol prophylaxis postoperatively
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study: 29405886

Group type: EXPERIMENTAL
Intervention: TIF 2.0 with EsophyX2 device
Number of subjects: 63
Study: 27359325

Group type: EXPERIMENTAL
Intervention: DM-HCC risk score based on age > 65 years, low triglyceride levels, and high gamma-glutamyl transferase levels
Number of subjects: 3544

Group type: EXPERIMENTAL
Intervention: Cumulative incidences of HCC
Number of subjects: 3544

Group type: EXPERIMENTAL
Intervention: Age > 65 years, low triglyceride levels, high gamma-glutamyl transferase levels
Number of subjects: 3544

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model
Number of subjects: 3544
Study: 25719902

Group type: EXPERIMENTAL
Intervention: Health education intervention consisting of an address by a trained teacher, a video show, and a leaflet given to each pupil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monitoring alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 60
Study: 23696676

Group type: EXPERIMENTAL
Intervention: Combination pill (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Two pills (angiotensin II receptor blocker and thiazide diuretic)
Number of subjects: 203
Study: 19828203

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Number of subjects: 573
Study: 18154823

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (0.8 microg/kg bolus and 0.113 microg/kg/h infusion)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both methylprednisolone and triiodothyronine
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Trial management
Number of subjects: 182
Study: 16869873

Group type: EXPERIMENTAL
Intervention: UVA 15 J/cm(2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: UVA 5 J/cm(2)
Number of subjects: 20
Study: 14708610

Group type: EXPERIMENTAL
Intervention: Ultraviolet B sunscreen (sun protection factor 5.2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Broad-spectrum ultraviolet A + B sunscreen (sun protection factor 6.2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no sunscreen)
Number of subjects: 75
Study: 11132506

Group type: EXPERIMENTAL
Intervention: Publications ranked by quality of evidence
Number of subjects: 2848
Study: 9165973

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.25 mg.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 1547191

Group type: EXPERIMENTAL
Intervention: Probucol 1 g/day (4 tablets)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Probucol 250 mg/day (1 tablet)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whole study group
Number of subjects: 17
Study: 4059587

Group type: EXPERIMENTAL
Intervention: 50 mg nalmefene
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30259252

Group type: EXPERIMENTAL
Intervention: Titanium-coated mesh
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard polypropylene mesh
Number of subjects: 102
Study: 30594227

Group type: EXPERIMENTAL
Intervention: 1 g of Tranexamic acid (TXA) by intravenous injection immediately after the umbilical cord is cut or clamped
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 10000
Study: 26524725

Group type: COMPARATOR
Intervention: Home-based intervention program (HBIP)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Clinic-based intervention program (CBIP)
Number of subjects: 178
Study: 24557112

Group type: EXPERIMENTAL
Intervention: N2O (FIO2 = 0.5)
Number of subjects: 50

Group type: COMPARATOR
Intervention: O2 (100% oxygen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: N2O/O2 mixture (FIO2 = 0.5)
Number of subjects: 50
Study: 21839467

Group type: EXPERIMENTAL
Intervention: Mild fluid restriction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard fluid management
Number of subjects: 64
Study: 20141565

Group type: EXPERIMENTAL
Intervention: Vitamin D 40,000 IU per week (DD group)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Vitamin D 20,000 IU per week (DP group)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo (PP group)
Number of subjects: 438
Study: 18678826

Group type: EXPERIMENTAL
Intervention: 1,800 mg/d EPA-DHA for 26 weeks
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: 400 mg/d EPA-DHA for 26 weeks
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 302
Study: 15672985

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 100 mg, 200 mg, 100 mg, and 200 mg administered at 21:45, 23:45, 01:45, and 03:45
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 30
Study: 12799091

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/d
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/d
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Losartan 2 x 50 mg/d
Number of subjects: 118
Study: 10232433

Group type: EXPERIMENTAL
Intervention: MRI measurements of the liver (T2 relaxation time)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Average serum ferritin levels
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TLC (% predicted)
Number of subjects: 21
Study: 8038755

Group type: EXPERIMENTAL
Intervention: ANF (0.01 fmol/Kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (50 mL of isotonic saline)
Number of subjects: 20
Study: 2662830

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 300 mg of pentoxifylline (15 mL ampoules) administered over three hours twice daily.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo: 15 mL of a 0.9% NaCl solution in 250 mL of 5% laevulose, administered over three hours twice daily.
Number of subjects: 154
Study: 4581347

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg single dose)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol (30 mg three times a day for one month)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30745260

Group type: EXPERIMENTAL
Intervention: Adjunctive cervical non-invasive vagus nerve stimulation (nVNS) for 2 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both groups (nVNS and sham)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Adjunctive cervical non-invasive vagus nerve stimulation (nVNS) and sham stimulation
Number of subjects: 48
Study: 23604570

Group type: EXPERIMENTAL
Intervention: Infliximab therapy at 5 mg/kg initially given at 0, 2, 6 weeks, then at 8-week intervals.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) as an indicator.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) >0.5 mg/dL.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Time to loss of response (LOR).
Number of subjects: 57
Study: 23107346

Group type: EXPERIMENTAL
Intervention: L-theanine + placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Caffeine + placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20131184

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of 20 ml of bone marrow cells (BMC) after successful primary PCI
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bare metal stenting of the infarct-related artery (IRA) without BMC administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of 20 ml of BMC
Number of subjects: 40
Study: 18167502

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 16173965

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study: 14522731

Group type: EXPERIMENTAL
Intervention: High-protein diet (30:40:30 ratio of protein to carbohydrate to fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet (15:55:30 ratio of protein to carbohydrate to fat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12
Study: 10908007

Group type: EXPERIMENTAL
Intervention: 16-week Matrix program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual treatment offered by the programs at the eight participating sites
Number of subjects: 0